-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In the secondary market, in the second half of 2021, due to the IPO of many Biotech companies that went public in that year, investor confidence continued to decline, and the entire Biotech industry seemed to be facing a cold winter
.
However, in the primary market, financing in the global biotechnology sector is still hot as a whole
.
According to the Evaluate report, private financing in the biotech sector will reach $28.
5 billion in 2021, a 26% increase from 2020
.
Judging from the primary market financing of biotech companies in 2021 sorted out by the US pharmaceutical website Fierce Pharma, the top list of biotech companies in private financing in 2021 includes ElevateBio, EQRx, Neumora, Laronde, etc.
There are also two Chinese companies, they are Aibo Bio and Insilico Intelligence
.
Expro Bio: Completed three rounds of financing in the year with a total of over US$1.
1 billion Expro Bio has performed particularly well.
In 2021, a total of three rounds of financing will be completed.
In April 2021, the B round of financing of RMB 600 million will be completed, and in August of that year Completed US$720 million in Series C financing; completed US$300 million in Series C+ financing in November of that year, with a cumulative financing of over US$1.
1 billion, far surpassing his family and becoming the world's largest single-round financing company in 2021
.
According to the data, Aibo Bio was founded by Dr.
InBev, and the company focuses on the research and development of mRNA drugs and vaccines
.
Some analysts believe that the reason why Aibo Bio is "loved" is mainly because the mRNA vaccine ARCoVaX, which it participated in the development of, has entered the end of the third phase of clinical trials
.
According to the research activity information released by Abbott partner Watson Bio in March 2022, the on-site work of ARCoVaX’s Phase III clinical trials in China is basically over, and data collation and continuous serum testing are underway
.
The product is also the first mRNA vaccine approved for clinical trials in China, and investors believe that it has broad investment prospects
.
In the Series C financing of up to US$720 million, including Temasek, Invesco Development Market Fund, Zhenggu Capital, GL Ventures, Yunfeng Capital, Eli Lilly Asia Ventures, Boyu Capital, Qiming Venture Partners, Highlight Capital and other large investments Institutions are on the list of participating investment, which shows that these institutions are optimistic about the company
.
It is reported that Aibo and its partners already have an annual production capacity of 400 million doses of vaccines, and may further increase the production capacity when they are successfully approved
.
Insilicon: Completed $255 million in Series A financing Insilicon completed its $255 million Series A in June 2021, and has secured Warburg Pincus, Qiming Ventures, Pavilion Capital, Eli Lilly Asia Ventures, Innovation The favor of large investment institutions such as factories shows its popularity with capital
.
Insilicon Intelligence is an end-to-end artificial intelligence (AI)-driven clinical-stage drug discovery company focused on leveraging artificial intelligence to advance the development of innovative therapeutics
.
For the first time in the world, it used AI to discover a new mechanism of preclinical candidate compounds for the treatment of idiopathic pulmonary fibrosis (IPF), which greatly refreshed the speed and low-cost record of new drug development
.
The company has also built three efficient AI drug development platforms for different stages of innovative drug development, including PandaOmics, a new drug target discovery platform, Chemistry42, a deep molecular generation reinforcement learning system that can be used to design novel molecules that do not exist in known technologies, and a clinical InClinico, a test success rate prediction platform
.
Up to now, Insilicon has nominated 6 preclinical drug candidates discovered or designed by AI, including the preclinical drug candidate targeting the tumor immune target QPCTL in cooperation with Fosun Pharma
.
In addition, Insilicon's first internal self-developed pulmonary fibrosis project also successfully completed the Phase 0 micro-dose group human trial and entered the Phase I clinical trial stage
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
However, in the primary market, financing in the global biotechnology sector is still hot as a whole
.
According to the Evaluate report, private financing in the biotech sector will reach $28.
5 billion in 2021, a 26% increase from 2020
.
Judging from the primary market financing of biotech companies in 2021 sorted out by the US pharmaceutical website Fierce Pharma, the top list of biotech companies in private financing in 2021 includes ElevateBio, EQRx, Neumora, Laronde, etc.
There are also two Chinese companies, they are Aibo Bio and Insilico Intelligence
.
Expro Bio: Completed three rounds of financing in the year with a total of over US$1.
1 billion Expro Bio has performed particularly well.
In 2021, a total of three rounds of financing will be completed.
In April 2021, the B round of financing of RMB 600 million will be completed, and in August of that year Completed US$720 million in Series C financing; completed US$300 million in Series C+ financing in November of that year, with a cumulative financing of over US$1.
1 billion, far surpassing his family and becoming the world's largest single-round financing company in 2021
.
According to the data, Aibo Bio was founded by Dr.
InBev, and the company focuses on the research and development of mRNA drugs and vaccines
.
Some analysts believe that the reason why Aibo Bio is "loved" is mainly because the mRNA vaccine ARCoVaX, which it participated in the development of, has entered the end of the third phase of clinical trials
.
According to the research activity information released by Abbott partner Watson Bio in March 2022, the on-site work of ARCoVaX’s Phase III clinical trials in China is basically over, and data collation and continuous serum testing are underway
.
The product is also the first mRNA vaccine approved for clinical trials in China, and investors believe that it has broad investment prospects
.
In the Series C financing of up to US$720 million, including Temasek, Invesco Development Market Fund, Zhenggu Capital, GL Ventures, Yunfeng Capital, Eli Lilly Asia Ventures, Boyu Capital, Qiming Venture Partners, Highlight Capital and other large investments Institutions are on the list of participating investment, which shows that these institutions are optimistic about the company
.
It is reported that Aibo and its partners already have an annual production capacity of 400 million doses of vaccines, and may further increase the production capacity when they are successfully approved
.
Insilicon: Completed $255 million in Series A financing Insilicon completed its $255 million Series A in June 2021, and has secured Warburg Pincus, Qiming Ventures, Pavilion Capital, Eli Lilly Asia Ventures, Innovation The favor of large investment institutions such as factories shows its popularity with capital
.
Insilicon Intelligence is an end-to-end artificial intelligence (AI)-driven clinical-stage drug discovery company focused on leveraging artificial intelligence to advance the development of innovative therapeutics
.
For the first time in the world, it used AI to discover a new mechanism of preclinical candidate compounds for the treatment of idiopathic pulmonary fibrosis (IPF), which greatly refreshed the speed and low-cost record of new drug development
.
The company has also built three efficient AI drug development platforms for different stages of innovative drug development, including PandaOmics, a new drug target discovery platform, Chemistry42, a deep molecular generation reinforcement learning system that can be used to design novel molecules that do not exist in known technologies, and a clinical InClinico, a test success rate prediction platform
.
Up to now, Insilicon has nominated 6 preclinical drug candidates discovered or designed by AI, including the preclinical drug candidate targeting the tumor immune target QPCTL in cooperation with Fosun Pharma
.
In addition, Insilicon's first internal self-developed pulmonary fibrosis project also successfully completed the Phase 0 micro-dose group human trial and entered the Phase I clinical trial stage
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
